Evaluation of anti-cancer effects of carnosine and melittin-loaded niosomes in MCF-7 and MDA-MB-231 breast cancer cells

Frontiers in Pharmacology

Pharmacology

Sara F. Gaafar¹  Mohamed M. A. Hussein¹  Haitham Eldoumani²  Ahmed Abdelfattah-Hassan³  Khalid Saad Alharbi⁴  Tariq G. Alsahli⁵  Sami I. Alzarea⁵  Walaa M. Essawi⁶  Hassan Y. Al-Hejaili⁷ 

[1] Biochemistry Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt;Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt;Department of Anatomy and Embryology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt;Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt;Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia;Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia;Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt;Pharmaceutical Care Department, King Salman Bin Abdulaziz Medical City, Ministry of Health, Medina, Saudi Arabia;

关键词: carnosine;    melittin;    niosome;    breast cancer cells;    cell cycle analysis;    miRNA-183;   

DOI  :  10.3389/fphar.2023.1258387

 received in 2023-07-13, accepted in 2023-09-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: We investigated the anti-cancer effect of carnosine-loaded niosomes (Car-NIO) and melittin-loaded niosomes (Mel-NIO) with olaparib in breast cancer cell lines (MCF-7 and MDA-MB-231).Methods: The thin film method was used for preparing the niosomes and characterized in terms of morphology, size, and polydispersity index (PDI). We further evaluated the impact of these peptides on breast cancer cells viability, RT-qPCR assays, malondialdehyde (MDA) activity, and cell cycle progression, to determine if these are linked to carnosine and melittin’s anti-proliferative properties.Results: Car-NIO and Mel-NIO in vitro study inhibited cancer cell viability. They have also upregulated the expression of protein 53 (P53), BCL2-Associated X Protein (Bax), caspase-9, caspase-3, programmed cell death 4 (PDCD4), and Forkhead box O3 (FOXO3), while downregulated the expression of B-cell lymphoma 2 (Bcl2), poly (ADP-ribose) polymerase (PARP 1), and MicroRNA-183 (miRNA-183). The MCF-7 cells were arrested at the G2/M phase in Car-NIO, on the other hand, the MDA-MB-231 cells were arrested at the S phase. While the Mel-NIO and olaparib arrested the MCF-7 and MDA-MB-231 cells at the G0/1 phase.Conclusion: Our study successfully declared that Mel-NIO had more anti-cancer effects than Car-NIO in both MCF-7 and MDA-MB-231 breast cancer cells.

【 授权许可】

Unknown   
Copyright © 2023 Hussein, Abdelfattah-Hassan, Eldoumani, Essawi, Alsahli, Alharbi, Alzarea, Al-Hejaili and Gaafar.